Cantor Fitzgerald is in the business to make money for their clients. They won't make a frivolous call. Opko long's hang on because it will be a great long-term investment.
Cantor Fitzgerald Obviously knows something OPK going to $20-30
Premarket analyst action - healthcare
Aug. 18, 2017 7:42 AM ET|By: Douglas W. House, SA News Editor
Opko Health (NYSEMKT:OPK) initiated with Overweight rating and $20 (240% upside) price target by Cantor Fitzgerald. Shares are up 3% premarket on average volume.
100% of the BUY SIde analysts I know have a sell rating and a $4 price target for OPK.
Just bought in.This stock is as oversold as the whole group is/A lot of money to be made with these and am looking at buying a bunch today. DRRX DEPO BCRX OPK all on fire sale and opk rumor I have heard may be in negotiations for a buyout.Would make sense here.
March 14, 2017, 2:07 PM EDT ($8.14)
In a research report released today, Guggenheim analyst Louise Chen initiated coverage on shares of Opko Health Inc. (NASDAQ:OPK) with a Buy rating and price target of $25
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Louise Chen has a yearly average return of -13.4% and a 35% success rate. Chen is ranked #4405 out of 4517 analysts.
Let's all take a little PEEP at the "Warren Buffet of Biotech" portfolio!
OPK June 2015 $19 Today $6! (SOON TO BE $5) (WOW)
COCP March 1 2014 $1.48 Today .19! )
MSLP 9/1/2014 $13.20 Today $1.68!
PGLC 2/1/15 $7.20 Today $2.89
NVCN 12/5/16 $2.04 Today $1.00
MBVX 5/1/14 $11.44 Today $.64!
RXII 1/1/15 10.90 Today .57!
DRNE 3/2015 $5.60 Today .94
Boy I tell you what as if it can't get any better than Frost telling investors that he has a lot of shorts that are his friends, and that he "has always enjoyed a nice big short position," then to top it off he gets on Cramer MM recently and says,
"I invest in what I know!"
At this price i think OPK is a great investment.
,Poor longs must be shaking their heads in disbelief. Before the market opened longs were fantasizing about the "great" news from Cantor Fitzgerald. Opko in the green, price rising, who knows maybe a 20 or even 30 cent gain today. Market opens and slowly Opko share price begins to sink once more. Gain was 20 cents, then 15, then 10 now 4 cents, and soon we see red. So sad.
OPKO Health Inc. (OPK, $6.06, Overweight, Target: $20.00) Louise Chen (212-915-1794, Louise.Chen@cantor.com)
OPK Is A Company You Can Grow With; Initiating Coverage With Overweight Investment Summary. We are initiating coverage of OPKO Health's (OPK) stock with an Overweight rating and a 12-month PT of $20. OPK has a diversified product portfolio focused on both diagnostics and pharmaceuticals. The company also has a robust brand drug pipeline targeting large market opportunities. We think that the sales and earnings potential of the company's business is underappreciated and that upward earnings revisions to levels not reflected in consensus expectations should drive the stock higher. We expect upward earnings revisions to be driven by: 1) the uptake of Rayaldee, 2) commercialization of OPK's branded drug pipeline, and 3) BioReference sales growth and margin expansion. · Expect Rayaldee sales to pick up the pace. Sales force expansion for Rayaldee is under way, and OPK has made substantial progress in obtaining formulary access for Rayaldee. With more-extensive insurance coverage, OPK is continuing to expand its field-based sales force to 70 representatives from the original 35. Also, on 6/22/17, OPK announced that the Kidney Disease Improving Global Outcomes (KDIGO) organization had updated its Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The update supports the use of Rayaldee over the existing standard of care. · Robust drug pipeline advancing toward commercialization. OPK expects to initiate five Phase 2 clinical trials in 2H17 and early-2018. These are: 1) Rayaldee line extension in dialysis patients with SHPT; 2) OPK88004, an orally administered selective androgen receptor modulator (SARM); 3) OPK88003, a once-weekly oxyntomodulin dual GLP1-Glucagon agonist for type 2 diabetes and obesity; 4) OPK88002, an NK-1 antagonist to treat pruritus (severe itching); and 5) OPK88001, an oligonucleotide-based AntagoNAT for the treatment of Dravet Syndrome. We have not included any sales for OPK's pipeline drugs in our financial model. · BioReference sales potential is underappreciated. BioReference Laboratories seems well-positioned to accelerate revenue growth and expand operating margins through 2H17 and 2018, given that OPK’s continued investment in new systems provides better financial data and more information about customers, products and sales. The new leadership team is introducing programs that it expects to benefit all aspects of the business. GeneDx, BioReference's genetic testing unit, continues to expand its innovative tests and services offerings and to further develop its relationships with healthcare providers and systems. · Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20. Our DCF analysis results in a 12-month share price of $25 and our multiples analysis in a 12-month share price of $17.
After seeing and listening to Dr. Frost on Cramers program last week I decided to purchase more shares. Not to trade but to hold for the long term. I traded shares of Opk several years ago when I did not feel comfortable about being long. Now things are different. Commercials about 4 K score will be on television soon, BRLI's revenues are increasing etc. I am sure Frost did not want to talk about the stock price because he is buying many shares almost daily at discount prices. Good luck longs and remember the shorts will be gone soon ( by December or sooner) and this message board will be more interesting.
@Dbrewerm You sound like a little kid whining about getting punched in the face on the playgound. Do something about it if you think there is something that can be done. Management does not control the market manipulation any more than we do. Look at all of the other stocks suffering from naked shorting and manipulation, they can't do anything either. Even Tesla was on this list at one time. The blame should go to the SEC and their failure to enforce clear policy and regulation.
Descending triangle at its apex right now. Most of the time price breaks down, however at the end of June OPK broke out above trend resistance when it went above $7 and threw back to the triangle which happens often in a bottoming process. Still haven't violated the horizontal support and remain stuck on the throw back to the overhead resistance that was violated in June. This will resolve any day now. Perhaps tomorrow actually.
I finally have some good news for the longs. After 2 straight months of adding to their short position LADENBURG THALMANN seems to have stopped short selling. Massive short position. And who's on the board? Oh that's right his "friends." HaHa
OPK was just part of a massacre today on all of them when the mkt melted.Jerry your posts are nonsense and think you should slow down on showing your stock credos.When a person only brings personal attacks to any board their posts are as worthless as teats on a pig.Also all these people on boards who claim there short are probably unable to buy any stock.They are bitter because they have lost all their money and want everyone else to join them.Tomorrow will be a bit of a test we will see.
Yes we seen yesterday a aftermarket turn that should bleed into today.Life be good.Also I said wed that something was up and we had the announcement with the Vaco deal.I think there is still something more,we will see.But these shorts may have to start covering and that could be dramatic.
THE HAPLESS SLOPKO GROUPIES!
BUSTED! BROKE! WRONG! DOPES! DOOFUSES! IDIOTS! CLUELESS! ALL DAY McDonald's BREAKFAST EATERS! DEGENERATE GAMBLERS! LAUGHED AT BY THEIR RELATIVES! CONSIDERED MORONS BY THEIR NEIGHBORS! UNQUALIFIED TO INVEST IN THE STOCK MARKET! ARROGANT A WHOLES! PERFECT PEOPLE TO MAKE FUN OF AND MOCK! POOR! GOING TO LIVE IN POVERTY IN THEIR OLD AGE! MOST EVERYONE IS SUPERIOR TO THEM!
frost bought another 50k shares yesterday. hopefully one day he will be right. amazing a guy with over 164 million shares hasn't made a penny yet.
Thanks Mike, for posting the nakedshortreport.com info. That was an interesting read. Makes me wonder how this is affecting trend data for this stock. We should be trading in the $10 to $15 range already, but the huge naked short influence is keeping us down and driving us lower. Frost can't do anything about it. The only way to break out is real and sustainable revenue that will bring in big institutional buyers who can overpower the shorts. This will happen soon enough as Rayaldee continues exponential growth and 4K hits the airwaves. Keep the faith and stay positive because we will make money.
Naked Short Report, Nasdaq and NYSE Naked Short Positions, Short Selling Interest
Naked Short Report - track short selling interest on NASDAQ and NYSE STOCKS, check daily short interest, naked short data and short squeeze stock perfomance
The Shorts are killing this company, its managers, workers and shareholders.